New data for candidate drug, Belinostat, published by Danish biotech Topotarget on Thursday will bring with it a number of positive side effects, says analyst Mick Cooper from London, UK-based Edison Investment Research Limited.
The data confirm Belinostat’s potential and increase the likelihood of the drug gaining approval next year. Meanwhile, the positive data are bound to make it easier for Topotarget to find a partner for the drug in Europe.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app